Cessation of gonadotropin-releasing hormone antagonist on triggering day in flexible multiple-dose protocol: A randomized controlled study.

Chang HJ, Lee JR, Jee BC, Suh CS, Lee WD, Kim SH

Clinical and experimental reproductive medicine30 Jun 2013Cited by 6 (Europe PMC)

PMID23875164PMCIDPMC3714433DOI10.5653/cerm.2013.40.2.83PepBankPUB-23875164

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In IVF patients, cetrorelix cessation schedules did not differ significantly in stimulation duration, gonadotropin dose, estradiol or retrieved oocytes.
In plain wordsIn IVF patients, cetrorelix cessation schedules did not differ significantly in stimulation duration, gonadotropin dose, estradiol or retrieved oocytes.
Peptide
Cetrorelix
Outcome
No significant changeStimulation duration, gonadotropin dose, estradiol and retrieved oocytes
Study
n = 86
Comparator
Cetrorelix continued through hCG triggering day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/dayAs given in this study (human).
Source sentences
Summary
The duration of ovarian stimulation, total dose of gonadotropins, serum estradiol levels on hCG administration day, and number of oocytes retrieved were not significantly different between the two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 86 women who underwent controlled ovarian hyperstimulation with recombinant FSH and GnRH antagonist flexible multiple-dose protocols were recruited and prospectively randomized into the conventional group (group A) or cessation group (group B).
Summary · context
The GnRH antagonist, 0.25 mg/day of cetrorelix, was started when the leading follicle reached 14 mm in diameter and was continuously administered until the hCG triggering day (group A, 43 cycles) or until the day before hCG administration (group B, 43 cycles).
Report a problemFND-2387516401
02HumanRandomized controlled trialEfficacy outcome
In IVF patients, stopping cetrorelix before triggering reduced antagonist use versus continuation through triggering (2.5±0.9 versus 3.2±0.8 ampoules, p<0.05).
In plain wordsIn IVF patients, stopping cetrorelix before triggering reduced antagonist use compared with continuation through triggering.
Peptide
Cetrorelix
Outcome
DecreaseTotal antagonist dose
Study
n = 86
Comparator
Cetrorelix continued through hCG triggering day
Outcome group
Drug Exposure · Reproductive and sexual health
Studied dose
0.25 mg/dayAs given in this study (human).
Measurements
Antagonist dose
2.5 ampoules
cessation
Antagonist dose
3.2 ampoules
continuation
Source sentences
Summary
The total dose of GnRH antagonist was significantly lower in group B than group A (2.5±0.9 vs. 3.2±0.8 ampoules, p<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 86 women who underwent controlled ovarian hyperstimulation with recombinant FSH and GnRH antagonist flexible multiple-dose protocols were recruited and prospectively randomized into the conventional group (group A) or cessation group (group B).
Summary · context
The GnRH antagonist, 0.25 mg/day of cetrorelix, was started when the leading follicle reached 14 mm in diameter and was continuously administered until the hCG triggering day (group A, 43 cycles) or until the day before hCG administration (group B, 43 cycles).
Report a problemFND-2387516402
03HumanRandomized controlled trialEfficacy outcome
In IVF patients, mature oocyte proportions did not differ significantly between cetrorelix cessation and continuation (70.7% versus 66.7%).
In plain wordsIn IVF patients, mature oocyte proportions did not differ significantly between cetrorelix cessation and continuation.
Peptide
Cetrorelix
Outcome
No significant changeMature oocyte proportion
Study
n = 86
Comparator
Cetrorelix continued through hCG triggering day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/dayAs given in this study (human).
Measurements
Mature oocytes
70.7%
cessation
Mature oocytes
66.7%
continuation
Source sentences
Summary
The proportion of mature oocytes and fertilization rate were not significantly different in group B than group A (70.7% vs. 66.7%; 71.1% vs. 66.4%, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 86 women who underwent controlled ovarian hyperstimulation with recombinant FSH and GnRH antagonist flexible multiple-dose protocols were recruited and prospectively randomized into the conventional group (group A) or cessation group (group B).
Summary · context
The GnRH antagonist, 0.25 mg/day of cetrorelix, was started when the leading follicle reached 14 mm in diameter and was continuously administered until the hCG triggering day (group A, 43 cycles) or until the day before hCG administration (group B, 43 cycles).
Report a problemFND-2387516404
04HumanRandomized controlled trialEfficacy outcome
In IVF patients, fertilization rates did not differ significantly between cetrorelix cessation and continuation (71.1% versus 66.4%).
In plain wordsIn IVF patients, fertilization rates did not differ significantly between cetrorelix cessation and continuation.
Peptide
Cetrorelix
Outcome
No significant changeFertilization rate
Study
n = 86
Comparator
Cetrorelix continued through hCG triggering day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/dayAs given in this study (human).
Measurements
Fertilization rate
71.1%
cessation
Fertilization rate
66.4%
continuation
Source sentences
Summary
The proportion of mature oocytes and fertilization rate were not significantly different in group B than group A (70.7% vs. 66.7%; 71.1% vs. 66.4%, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 86 women who underwent controlled ovarian hyperstimulation with recombinant FSH and GnRH antagonist flexible multiple-dose protocols were recruited and prospectively randomized into the conventional group (group A) or cessation group (group B).
Summary · context
The GnRH antagonist, 0.25 mg/day of cetrorelix, was started when the leading follicle reached 14 mm in diameter and was continuously administered until the hCG triggering day (group A, 43 cycles) or until the day before hCG administration (group B, 43 cycles).
Report a problemFND-2387516405
05HumanRandomized controlled trialEfficacy outcome
In IVF patients, implantation rates did not differ significantly between cetrorelix cessation and continuation.
In plain wordsIn IVF patients, implantation rates did not differ significantly between cetrorelix cessation and continuation.
Peptide
Cetrorelix
Outcome
No significant changeImplantation rate
Study
n = 86
Comparator
Cetrorelix continued through hCG triggering day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/dayAs given in this study (human).
Source sentences
Summary
There were no significant differences in the implantation or clinical pregnancy rates.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 86 women who underwent controlled ovarian hyperstimulation with recombinant FSH and GnRH antagonist flexible multiple-dose protocols were recruited and prospectively randomized into the conventional group (group A) or cessation group (group B).
Summary · context
The GnRH antagonist, 0.25 mg/day of cetrorelix, was started when the leading follicle reached 14 mm in diameter and was continuously administered until the hCG triggering day (group A, 43 cycles) or until the day before hCG administration (group B, 43 cycles).
Report a problemFND-2387516406
06HumanRandomized controlled trialEfficacy outcome
In IVF patients, clinical pregnancy rates did not differ significantly between cetrorelix cessation and continuation.
In plain wordsIn IVF patients, clinical pregnancy rates did not differ significantly between cetrorelix cessation and continuation.
Peptide
Cetrorelix
Outcome
No significant changeClinical pregnancy rate
Study
n = 86
Comparator
Cetrorelix continued through hCG triggering day
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/dayAs given in this study (human).
Source sentences
Summary
There were no significant differences in the implantation or clinical pregnancy rates.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 86 women who underwent controlled ovarian hyperstimulation with recombinant FSH and GnRH antagonist flexible multiple-dose protocols were recruited and prospectively randomized into the conventional group (group A) or cessation group (group B).
Summary · context
The GnRH antagonist, 0.25 mg/day of cetrorelix, was started when the leading follicle reached 14 mm in diameter and was continuously administered until the hCG triggering day (group A, 43 cycles) or until the day before hCG administration (group B, 43 cycles).
Report a problemFND-2387516407
07HumanNon-randomized trialEfficacy outcome
In IVF patients, no premature luteinization occurred with either cetrorelix cessation schedule.
In plain wordsIn IVF patients, no premature luteinization occurred with either cetrorelix cessation schedule.
Peptide
Cetrorelix
Outcome
Not applicablePremature luteinization
Study
n = 86
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.25 mg/dayAs given in this study (human).
Source sentences
Summary
There was no premature luteinization in any of the subjects.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 86 women who underwent controlled ovarian hyperstimulation with recombinant FSH and GnRH antagonist flexible multiple-dose protocols were recruited and prospectively randomized into the conventional group (group A) or cessation group (group B).
Summary · context
The GnRH antagonist, 0.25 mg/day of cetrorelix, was started when the leading follicle reached 14 mm in diameter and was continuously administered until the hCG triggering day (group A, 43 cycles) or until the day before hCG administration (group B, 43 cycles).
Report a problemFND-2387516403

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.